{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-003318","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.719331+00:00","generated_at":"2026-06-04T14:40:01.589445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pharma-Bio Serv Q1 revenue down 44% to $2.4M; swings to net loss of $270.7K","bullets":["Revenue for Q1 ended Jan 31, 2024: $2.4M, down $1.9M from $4.3M in prior-year quarter.","Net loss of ~$270.7K vs net income of $426.4K in the same quarter last year.","CEO cites planned investments in business development to drive future growth and profitability.","No specific financial guidance or outlook provided for fiscal year 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-003318","json":"https://secwatch.observer/filing/0001654954-24-003318.json","markdown":"https://secwatch.observer/filing/0001654954-24-003318.md","text":"https://secwatch.observer/filing/0001654954-24-003318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/0001654954-24-003318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:40:01.589445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61c1d3fd51264d81ef26dcaf87726aa047ce3dea","claim":"Pharma-Bio Serv, Inc. reported the quarter ended January 31, 2024 results: revenue approximately $2.4 million, net income approximately $270,700.","evidence_excerpt":"today announced that revenues for the quarter ended January 31, 2024 were approximately $2.4 million, a decrease of approximately $1.9 million when compared to the same period last year. Net loss for the quarter ended January 31, 2024 was approximately $270,700 compared to a net income of approximately $426,400 for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/0001654954-24-003318-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended January 31, 2024"},{"label":"Revenue","value":"approximately $2.4 million"},{"label":"Net income","value":"approximately $270,700"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}